Compare Stocks

Date Range: 

 Constellation PharmaceuticalsKiniksa PharmaceuticalsPliant TherapeuticsArcturus TherapeuticsZogenix
SymbolNASDAQ:CNSTNASDAQ:KNSANASDAQ:PLRXNASDAQ:ARCTNASDAQ:ZGNX
Price Information
Current Price$20.50$15.30$32.87$27.23$18.74
52 Week RangeBuyBuyBuyHoldBuy
MarketRank™
Overall Score1.21.72.01.61.7
Analysis Score3.43.53.53.13.4
Community Score2.42.44.62.62.8
Dividend Score0.00.00.00.00.0
Ownership Score0.02.51.71.71.7
Earnings & Valuation Score0.00.00.00.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldBuy
Consensus Price Target$40.33$37.00$49.20$69.58$59.00
% Upside from Price Target96.75% upside141.83% upside49.68% upside155.54% upside214.83% upside
Trade Information
Market Cap$982.24 million$1.04 billion$1.18 billion$716.69 million$1.05 billion
Beta2.80.03N/A3.011.6
Average Volume461,965476,570154,6641,085,341803,684
Sales & Book Value
Annual RevenueN/AN/A$57.05 million$20.79 million$3.65 million
Price / SalesN/AN/A20.6734.47286.56
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$8.23 per share$4.10 per shareN/A$1.70 per share$5.54 per share
Price / BookN/AN/A16.023.38
Profitability
Net Income$-85,550,000.00$-161,870,000.00$-630,000.00$-25,990,000.00$-419,500,000.00
EPS($3.04)($2.99)N/A($2.15)($3.90)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A20.83%-506.70%-8,758.48%
Return on Equity (ROE)-28.88%-53.65%16.55%-52.32%-53.91%
Return on Assets (ROA)-24.98%-49.11%8.33%-33.21%-36.49%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.05%N/AN/A0.06%N/A
Current Ratio15.81%15.20%27.91%11.21%4.58%
Quick Ratio15.81%15.20%27.91%11.21%4.58%
Ownership Information
Institutional Ownership PercentageN/A42.00%79.46%74.33%96.57%
Insider Ownership Percentage10.60%70.63%N/A12.60%3.50%
Miscellaneous
Employees15416878118218
Shares Outstanding47.91 million68.23 million35.88 million26.32 million55.81 million
Next Earnings Date8/4/2021 (Estimated)7/29/2021 (Estimated)8/10/2021 (Estimated)8/9/2021 (Estimated)8/4/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableOptionableOptionable
SourceHeadline
Zogenix to Participate in the BofA Securities 2021 Healthcare Conference - Yahoo FinanceZogenix to Participate in the BofA Securities 2021 Healthcare Conference - Yahoo Finance
finance.yahoo.com - May 11 at 6:54 PM
Zogenix to Participate in the BofA Securities 2021 Healthcare ConferenceZogenix to Participate in the BofA Securities 2021 Healthcare Conference
finance.yahoo.com - May 11 at 6:54 PM
Zogenix Launches Global Program to Boost Access to Fintepla - Dravet Syndrome NewsZogenix Launches Global Program to Boost Access to Fintepla - Dravet Syndrome News
dravetsyndromenews.com - May 11 at 1:53 PM
Zogenix: Q1 Earnings Snapshot - Miami HeraldZogenix: Q1 Earnings Snapshot - Miami Herald
miamiherald.com - May 8 at 12:59 PM
Zogenix (NASDAQ:ZGNX) Posts  Earnings Results, Misses Expectations By $0.02 EPSZogenix (NASDAQ:ZGNX) Posts Earnings Results, Misses Expectations By $0.02 EPS
americanbankingnews.com - May 7 at 4:32 PM
Zogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results - Yahoo FinanceZogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results - Yahoo Finance
finance.yahoo.com - May 7 at 3:18 PM
Zogenix (NASDAQ:ZGNX) Trading 6.6% Higher Zogenix (NASDAQ:ZGNX) Trading 6.6% Higher
americanbankingnews.com - May 7 at 12:44 PM
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Zogenix (ZGNX) and Dicerna Pharma (DRNA) - Smarter AnalystAnalysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Zogenix (ZGNX) and Dicerna Pharma (DRNA) - Smarter Analyst
smarteranalyst.com - May 7 at 10:14 AM
Does Zogenix, Inc. (ZGNX) Have What it Takes to be in Your Portfolio Friday? - InvestorsObserverDoes Zogenix, Inc. (ZGNX) Have What it Takes to be in Your Portfolio Friday? - InvestorsObserver
investorsobserver.com - May 7 at 10:14 AM
Zogenix: Q1 Earnings Snapshot - Westport NewsZogenix: Q1 Earnings Snapshot - Westport News
westport-news.com - May 7 at 10:14 AM
Zogenix EPS beats by $0.02, beats on revenue - Seeking AlphaZogenix EPS beats by $0.02, beats on revenue - Seeking Alpha
seekingalpha.com - May 7 at 12:26 AM
Recap: Zogenix Q1 Earnings - BenzingaRecap: Zogenix Q1 Earnings - Benzinga
benzinga.com - May 7 at 12:26 AM
Zogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results - GlobeNewswireZogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results - GlobeNewswire
globenewswire.com - May 6 at 7:26 PM
Zogenix Provides Corporate Update and Reports First Quarter 2021 Financial ResultsZogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 6 at 7:26 PM
Is Zogenix, Inc. (ZGNX) Stock at the Top of the Biotechnology Industry? - InvestorsObserverIs Zogenix, Inc. (ZGNX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
investorsobserver.com - May 6 at 2:25 PM
Zogenix (NASDAQ:ZGNX) Hits New 12-Month Low at $16.89Zogenix (NASDAQ:ZGNX) Hits New 12-Month Low at $16.89
americanbankingnews.com - May 6 at 12:44 PM
Global Needle-Free Injection Device Market 2021 Potential Growth | Zogenix, Antares Pharma, Akra Dermojet, Inovio, Eternity Healthcare – Jumbo News - Jumbo NewsGlobal Needle-Free Injection Device Market 2021 Potential Growth | Zogenix, Antares Pharma, Akra Dermojet, Inovio, Eternity Healthcare – Jumbo News - Jumbo News
jumbonews.co.uk - May 6 at 7:59 AM
$12.48 Million in Sales Expected for Zogenix, Inc. (NASDAQ:ZGNX) This Quarter$12.48 Million in Sales Expected for Zogenix, Inc. (NASDAQ:ZGNX) This Quarter
americanbankingnews.com - May 6 at 2:48 AM
Zogenix Q1 2021 Earnings Preview - Seeking AlphaZogenix Q1 2021 Earnings Preview - Seeking Alpha
seekingalpha.com - May 5 at 9:57 PM
Should You Buy Zogenix, Inc. (ZGNX) Stock After it Has Fallen 9.38% in a Week? - InvestorsObserverShould You Buy Zogenix, Inc. (ZGNX) Stock After it Has Fallen 9.38% in a Week? - InvestorsObserver
investorsobserver.com - May 5 at 11:55 AM
Outlook on the Needle Free Diabetes Management Global Market to 2029 - Development of Next Generation Glucose Sensors Presents Opportunities - PRNewswireOutlook on the Needle Free Diabetes Management Global Market to 2029 - Development of Next Generation Glucose Sensors Presents Opportunities - PRNewswire
prnewswire.com - May 4 at 6:48 PM
-$0.98 Earnings Per Share Expected for Zogenix, Inc. (NASDAQ:ZGNX) This Quarter-$0.98 Earnings Per Share Expected for Zogenix, Inc. (NASDAQ:ZGNX) This Quarter
americanbankingnews.com - May 4 at 12:26 PM
Booming Growth in Long-Acting Injectables Market Analysis Report 2021 and Forecast to 2027 with different segments, Key players are Eli Lilly,Pfizer,GlaxoSmithKline,Johnson & Johnson,Lupin Limited,Zogenix - Good News GumBooming Growth in Long-Acting Injectables Market Analysis Report 2021 and Forecast to 2027 with different segments, Key players are Eli Lilly,Pfizer,GlaxoSmithKline,Johnson & Johnson,Lupin Limited,Zogenix - Good News Gum
goodnewsgum.com - May 2 at 1:39 PM
Needle Free Diabetes Management Market to Witness Growth Acceleration by Top Key Players – Zogenix, 3M, Antares Pharma Inc., Glide Pharmaceutical Technologies, Injex Pharma AG, Pharmajet - Good News GumNeedle Free Diabetes Management Market to Witness Growth Acceleration by Top Key Players – Zogenix, 3M, Antares Pharma Inc., Glide Pharmaceutical Technologies, Injex Pharma AG, Pharmajet - Good News Gum
goodnewsgum.com - April 30 at 2:08 PM
Analysts Estimate Zogenix (ZGNX) to Report a Decline in Earnings: What to Look Out for - Yahoo FinanceAnalysts Estimate Zogenix (ZGNX) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
finance.yahoo.com - April 29 at 6:31 PM
Zogenix (NASDAQ:ZGNX) Stock Rating Upgraded by Zacks Investment ResearchZogenix (NASDAQ:ZGNX) Stock Rating Upgraded by Zacks Investment Research
marketbeat.com - April 23 at 5:59 AM
Zogenix (NASDAQ:ZGNX) Upgraded at Zacks Investment ResearchZogenix (NASDAQ:ZGNX) Upgraded at Zacks Investment Research
marketbeat.com - April 16 at 6:30 AM
DateCompanyBrokerageAction
4/7/2021Constellation PharmaceuticalsRoyal Bank of CanadaReiterated Rating
1/25/2021Constellation PharmaceuticalsBMO Capital MarketsUpgrade
9/24/2020Constellation PharmaceuticalsOppenheimerReiterated Rating
9/3/2020Constellation PharmaceuticalsBrookline Capital ManagementInitiated Coverage
8/9/2020Constellation PharmaceuticalsJefferies Financial GroupReiterated Rating
8/6/2020Constellation PharmaceuticalsHC WainwrightReiterated Rating
6/24/2020Constellation PharmaceuticalsJMP SecuritiesInitiated Coverage
3/11/2020Constellation PharmaceuticalsRobert W. BairdLower Price Target
3/11/2020Constellation PharmaceuticalsCowenReiterated Rating
2/13/2020Constellation PharmaceuticalsSunTrust BanksInitiated Coverage
11/24/2020Kiniksa PharmaceuticalsEvercore ISIInitiated Coverage
6/30/2020Kiniksa PharmaceuticalsThe Goldman Sachs GroupBoost Price Target
6/29/2020Kiniksa PharmaceuticalsBank of AmericaBoost Price Target
6/29/2020Kiniksa PharmaceuticalsWedbushBoost Price Target
3/11/2020Kiniksa PharmaceuticalsJPMorgan Chase & Co.Boost Price Target
3/11/2019Kiniksa PharmaceuticalsBarclaysInitiated Coverage
4/26/2021Pliant TherapeuticsBTIG ResearchInitiated Coverage
4/22/2021Pliant TherapeuticsPiper SandlerBoost Price Target
4/5/2021Pliant TherapeuticsCitigroupInitiated Coverage
4/5/2021Pliant TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
8/12/2020Pliant TherapeuticsNeedham & Company LLCReiterated Rating
3/8/2021Arcturus TherapeuticsB. RileyLower Price Target
3/2/2021Arcturus TherapeuticsRoth CapitalLower Price Target
1/7/2021Arcturus TherapeuticsWells Fargo & CompanyInitiated Coverage
12/29/2020Arcturus TherapeuticsRaymond JamesDowngrade
12/14/2020Arcturus TherapeuticsSmith Barney CitigroupBoost Price Target
12/2/2020ZogenixMizuhoReiterated Rating
8/6/2020ZogenixNorthland SecuritiesReiterated Rating
6/26/2020ZogenixWilliam BlairReiterated Rating
2/28/2020ZogenixLADENBURG THALM/SH SHReiterated Rating
2/14/2020ZogenixStifel NicolausReiterated Rating
1/21/2020ZogenixGuggenheimReiterated Rating
12/6/2019ZogenixPiper Jaffray CompaniesReiterated Rating
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.